Screening Compounds Against Leishmania Amastigotes
Author Information
Author(s): De Muylder Geraldine, Ang Kenny K. H., Chen Steven, Arkin Michelle R., Engel Juan C., McKerrow James H.
Primary Institution: University of California San Francisco
Hypothesis
The study aims to compare the efficiency of two screening methods for identifying compounds against Leishmania, focusing on the intracellular amastigote stage.
Conclusion
The study found that screening against the promastigote stage leads to numerous false positives and fails to identify all active compounds, highlighting the importance of targeting the intracellular amastigote stage.
Supporting Evidence
- 59 hits were identified in the promastigote assay, while 27 hits were found in the intracellular amastigote assay.
- Only one compound was specifically active against the intracellular amastigote stage.
- The promastigote assay led to a rate of 56% false positives.
Takeaway
Researchers tested a lot of different medicines to find out which ones can help fight a disease called leishmaniasis, and they discovered that some medicines work better when they look at the sick part of the bug inside the body.
Methodology
The study used a high-throughput screening assay to test a library of 909 bioactive compounds against both the promastigote and intracellular amastigote stages of Leishmania donovani.
Limitations
The promastigote assay may lead to false positives and does not account for the host cell's role in drug efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website